{ "run": { "id": "cmnr12mw402iip6585zcn7csv", "region": "US", "assetId": "cmnr12ldp02icp65897typi5j", "ticker": "BSX", "snapshotId": "cmnr12lgx02iep658xmremxe2", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:53.185Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12lgx02iep658xmremxe2", "assetId": "cmnr12ldp02icp65897typi5j", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 62.56, "dayLow": 62.125, "volume": 12875199, "dayHigh": 63.545, "currency": "USD", "prevClose": 61.86, "week52Low": 61.25, "week52High": 109.5 }, "fundamentals": { "pe": 70.8888888888889, "beta": 0.88394448274982, "epsTTM": 1.26, "fcfTTM": 1731000000, "growth": { "epsYoy": 0.5555555555555555, "revenueYoy": 0.1986624470054338 }, "sector": "Surgical & Medical Instruments & Apparatus", "margins": { "net": 0.1440669522765767, "gross": 0.6901464581050114, "operating": 0.1799840589817674 }, "website": "http://bostonscientific.com", "industry": "Medical device", "pegRatio": 4.25333333333334, "ebitdaTTM": 4076000000, "forwardPe": 31.0138888888889, "marketCap": 158700000000, "totalCash": 1965000000, "totalDebt": 11436000000, "debtEquity": 0.49361506660542, "quickRatio": 0.3612796469939327, "revenueTTM": 20074000000, "companyName": "BOSTON SCIENTIFIC CORP", "priceToBook": 3.98334282943387, "currentRatio": 1.616841331127045, "dividendYield": 0, "returnOnAssets": 0.0662194032926522, "returnOnEquity": 0.0847955902618282, "analystOpinions": null, "businessSummary": "Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.", "enterpriseValue": 141766380000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 59000, "sharesOutstanding": 1483885456, "enterpriseToEbitda": 34.78076054955839, "analystTargetMedian": null, "enterpriseToRevenue": 7.062188901066055, "operatingCashflowTTM": 4534000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:51.345Z" }, "results": [ { "id": "cmnr12mw802ikp658e868kywm", "runId": "cmnr12mw402iip6585zcn7csv", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"BSX\",\"currency\":\"USD\",\"current_price\":62.56,\"target_price_6m\":68.0,\"target_price_12m\":73.5,\"recommendation\":\"BUY\",\"confidence\":0.6,\"thesis_bullets\":[\"Strong revenue growth of ~20% YoY with diversified med-tech portfolio\",\"Stock near 52-week low, ~43% off highs, suggesting excessive pessimism priced in\",\"Forward PE of 31x reasonable for high-growth med-tech compounder\",\"Operating margin expansion potential from 18% toward 22% on scale\",\"Tariff and macro headwinds create near-term uncertainty but long-term thesis intact\"],\"key_drivers\":[{\"driver\":\"Electrophysiology segment growth (FARAPULSE adoption)\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Structural heart and cardiology pipeline expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating leverage driving margin expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue diversification across interventional specialties\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Tariff risk on medical device imports/components\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated debt load ($11.4B) limiting financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Multiple compression risk if growth decelerates\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation ($1.7B TTM) supporting reinvestment\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Tariff escalation materially impacting supply chain costs and margins\",\"Competitive pressure from Medtronic, Abbott, and J&J in key segments\",\"Regulatory setbacks on pipeline products or post-market device issues\",\"Macroeconomic slowdown reducing elective procedure volumes\",\"High valuation multiples leave limited margin of safety on disappointment\",\"Integration risk from acquisitions straining management bandwidth\"],\"assumptions\":{\"revenue_cagr_3y\":0.11,\"ebit_margin_target\":0.22,\"wacc\":0.09,\"terminal_multiple\":28},\"scenarios\":{\"bear\":{\"target_price\":52.0,\"prob\":0.25,\"notes\":\"Tariffs compress margins, growth slows to mid-single digits, multiple contracts to 25x forward PE.\"},\"base\":{\"target_price\":73.5,\"prob\":0.50,\"notes\":\"Revenue grows ~11%, margins expand modestly, market re-rates toward ~30x forward PE as macro stabilizes.\"},\"bull\":{\"target_price\":92.0,\"prob\":0.25,\"notes\":\"Tariff relief, accelerating pipeline adoption, margin beats drive re-rating toward 35x forward PE.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA approach. Forward EPS ~$2.02 implied by snapshot forward PE. Base case applies 30-32x on ~$2.30 FY+1 EPS estimate. Weighted scenario expected value ~$72.75 (16.3% upside), supporting BUY. Multiples still elevated vs. peers even at depressed price; confidence capped at 0.60 due to macro/tariff uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Tariff escalation materially impacting supply chain costs and margins", "Competitive pressure from Medtronic, Abbott, and J&J in key segments", "Regulatory setbacks on pipeline products or post-market device issues", "Macroeconomic slowdown reducing elective procedure volumes", "High valuation multiples leave limited margin of safety on disappointment", "Integration risk from acquisitions straining management bandwidth" ], "ticker": "BSX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Revenue grows ~11%, margins expand modestly, market re-rates toward ~30x forward PE as macro stabilizes.", "target_price": 73.5 }, "bear": { "prob": 0.25, "notes": "Tariffs compress margins, growth slows to mid-single digits, multiple contracts to 25x forward PE.", "target_price": 52 }, "bull": { "prob": 0.25, "notes": "Tariff relief, accelerating pipeline adoption, margin beats drive re-rating toward 35x forward PE.", "target_price": 92 } }, "confidence": 0.6, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.11, "terminal_multiple": 28, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Electrophysiology segment growth (FARAPULSE adoption)", "impact": "HIGH", "direction": "POS" }, { "driver": "Structural heart and cardiology pipeline expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating leverage driving margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Revenue diversification across interventional specialties", "impact": "MED", "direction": "POS" }, { "driver": "Tariff risk on medical device imports/components", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated debt load ($11.4B) limiting financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Multiple compression risk if growth decelerates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Strong FCF generation ($1.7B TTM) supporting reinvestment", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended forward PE and EV/EBITDA approach. Forward EPS ~$2.02 implied by snapshot forward PE. Base case applies 30-32x on ~$2.30 FY+1 EPS estimate. Weighted scenario expected value ~$72.75 (16.3% upside), supporting BUY. Multiples still elevated vs. peers even at depressed price; confidence capped at 0.60 due to macro/tariff uncertainty. Not investment advice.", "current_price": 62.56, "recommendation": "BUY", "thesis_bullets": [ "Strong revenue growth of ~20% YoY with diversified med-tech portfolio", "Stock near 52-week low, ~43% off highs, suggesting excessive pessimism priced in", "Forward PE of 31x reasonable for high-growth med-tech compounder", "Operating margin expansion potential from 18% toward 22% on scale", "Tariff and macro headwinds create near-term uncertainty but long-term thesis intact" ], "target_price_6m": 68, "target_price_12m": 73.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 44454, "createdAt": "2026-04-09T05:19:53.185Z", "usage": { "inputTokens": 3603, "outputTokens": 2037, "costUsd": 0.06894 } }, { "id": "cmnr12mw802inp658k14j3lv8", "runId": "cmnr12mw402iip6585zcn7csv", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"DCF with Exit Multiple\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"BSX\",\n \"currency\": \"USD\",\n \"current_price\": 62.56,\n \"target_price_6m\": 65.0,\n \"target_price_12m\": 70.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Strong revenue growth from innovative medical devices.\",\n \"Margin expansion through cost efficiencies and scale.\",\n \"Favorable demographic trends boosting healthcare demand.\",\n \"High current valuation may cap near-term upside.\",\n \"Solid cash flow supports debt management and R&D.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"New product launches\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approval timelines\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Healthcare spending increases\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Intensifying competition\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Supply chain disruptions\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"R&D innovation success\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Economic recession risk\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency exchange rates\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Regulatory hurdles for new devices\", \"Increased competition from peers\", \"Economic downturn reducing elective procedures\", \"Product recall or safety issues\", \"Rising input costs pressuring margins\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.18,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.08,\n \"terminal_multiple\": 25\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 55.0, \"prob\": 0.2, \"notes\": \"Growth slows and margins contract due to competition.\" },\n \"base\": { \"target_price\": 70.0, \"prob\": 0.6, \"notes\": \"Steady execution on growth and margin targets.\" },\n \"bull\": { \"target_price\": 85.0, \"prob\": 0.2, \"notes\": \"Accelerated adoption of new products and cost savings.\" }\n },\n \"method_notes\": \"DCF based on assumed FCF growth and exit multiple; BUY as 12M target implies ~12% upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "DCF with Exit Multiple", "risks": [ "Regulatory hurdles for new devices", "Increased competition from peers", "Economic downturn reducing elective procedures", "Product recall or safety issues", "Rising input costs pressuring margins" ], "ticker": "BSX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution on growth and margin targets.", "target_price": 70 }, "bear": { "prob": 0.2, "notes": "Growth slows and margins contract due to competition.", "target_price": 55 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption of new products and cost savings.", "target_price": 85 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.18, "terminal_multiple": 25, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "New product launches", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory approval timelines", "impact": "HIGH", "direction": "POS" }, { "driver": "Healthcare spending increases", "impact": "MED", "direction": "POS" }, { "driver": "Intensifying competition", "impact": "MED", "direction": "NEG" }, { "driver": "Supply chain disruptions", "impact": "MED", "direction": "NEG" }, { "driver": "R&D innovation success", "impact": "HIGH", "direction": "POS" }, { "driver": "Economic recession risk", "impact": "LOW", "direction": "NEG" }, { "driver": "Currency exchange rates", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF based on assumed FCF growth and exit multiple; BUY as 12M target implies ~12% upside. Not investment advice.", "current_price": 62.56, "recommendation": "BUY", "thesis_bullets": [ "Strong revenue growth from innovative medical devices.", "Margin expansion through cost efficiencies and scale.", "Favorable demographic trends boosting healthcare demand.", "High current valuation may cap near-term upside.", "Solid cash flow supports debt management and R&D." ], "target_price_6m": 65, "target_price_12m": 70 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 364, "createdAt": "2026-04-09T05:19:53.185Z", "usage": { "inputTokens": 2112, "outputTokens": 3081, "costUsd": 0.001885 } }, { "id": "cmnr12mw802ilp658xnwbh6ki", "runId": "cmnr12mw402iip6585zcn7csv", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"BSX\",\n \"currency\": \"USD\",\n \"current_price\": 62.56,\n \"target_price_6m\": 68.0,\n \"target_price_12m\": 73.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Farapulse PFA system adoption continues to drive strong electrophysiology market share gains.\",\n \"Recent price correction to 52-week lows offers an attractive entry point for long-term investors.\",\n \"Robust top-line growth of ~20% YoY demonstrates excellent execution across cardiovascular and med-surg segments.\",\n \"Forward P/E of 31x is reasonable given the 55% YoY EPS growth trajectory.\",\n \"High debt load and GLP-1 headwinds present ongoing but manageable risks to the valuation.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Farapulse PFA rollout\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Watchman FLX franchise growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1 drug adoption impacting cardiovascular TAM\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Hospital capital expenditure budgets\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Neuromodulation segment recovery\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supply chain and inflationary pressures\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration and pipeline execution\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Slower-than-expected adoption of Farapulse due to competitive PFA launches.\",\n \"Long-term cardiovascular TAM reduction from widespread GLP-1 agonist usage.\",\n \"Regulatory delays or FDA warning letters impacting new product approvals.\",\n \"High leverage (Debt/Equity 0.49) limiting future aggressive M&A capacity.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.12,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 25.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 52.0,\n \"prob\": 0.25,\n \"notes\": \"GLP-1 impacts materialize faster and competitors take PFA market share, compressing multiples.\"\n },\n \"base\": {\n \"target_price\": 73.0,\n \"prob\": 0.55,\n \"notes\": \"Farapulse continues strong trajectory, margins expand, and EPS grows at a normalized 15% CAGR.\"\n },\n \"bull\": {\n \"target_price\": 88.0,\n \"prob\": 0.2,\n \"notes\": \"Flawless pipeline execution and rapid margin expansion drive a return to historical premium multiples.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF (8.5% WACC, 25x terminal multiple) and a 35x forward P/E target. The recent pullback to $62.56 creates a favorable risk/reward, supporting a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Slower-than-expected adoption of Farapulse due to competitive PFA launches.", "Long-term cardiovascular TAM reduction from widespread GLP-1 agonist usage.", "Regulatory delays or FDA warning letters impacting new product approvals.", "High leverage (Debt/Equity 0.49) limiting future aggressive M&A capacity." ], "ticker": "BSX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Farapulse continues strong trajectory, margins expand, and EPS grows at a normalized 15% CAGR.", "target_price": 73 }, "bear": { "prob": 0.25, "notes": "GLP-1 impacts materialize faster and competitors take PFA market share, compressing multiples.", "target_price": 52 }, "bull": { "prob": 0.2, "notes": "Flawless pipeline execution and rapid margin expansion drive a return to historical premium multiples.", "target_price": 88 } }, "confidence": 0.7, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.12, "terminal_multiple": 25, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Farapulse PFA rollout", "impact": "HIGH", "direction": "POS" }, { "driver": "Watchman FLX franchise growth", "impact": "HIGH", "direction": "POS" }, { "driver": "GLP-1 drug adoption impacting cardiovascular TAM", "impact": "MED", "direction": "NEG" }, { "driver": "Hospital capital expenditure budgets", "impact": "MED", "direction": "POS" }, { "driver": "Neuromodulation segment recovery", "impact": "LOW", "direction": "POS" }, { "driver": "Supply chain and inflationary pressures", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration and pipeline execution", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF (8.5% WACC, 25x terminal multiple) and a 35x forward P/E target. The recent pullback to $62.56 creates a favorable risk/reward, supporting a BUY rating. Not investment advice.", "current_price": 62.56, "recommendation": "BUY", "thesis_bullets": [ "Farapulse PFA system adoption continues to drive strong electrophysiology market share gains.", "Recent price correction to 52-week lows offers an attractive entry point for long-term investors.", "Robust top-line growth of ~20% YoY demonstrates excellent execution across cardiovascular and med-surg segments.", "Forward P/E of 31x is reasonable given the 55% YoY EPS growth trajectory.", "High debt load and GLP-1 headwinds present ongoing but manageable risks to the valuation." ], "target_price_6m": 68, "target_price_12m": 73 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 31699, "createdAt": "2026-04-09T05:19:53.185Z", "usage": { "inputTokens": 2450, "outputTokens": 923, "costUsd": 0.015976 } }, { "id": "cmnr12mw802ijp658h3nz0j2c", "runId": "cmnr12mw402iip6585zcn7csv", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"BSX\",\"currency\":\"USD\",\"current_price\":62.56,\"target_price_6m\":67,\"target_price_12m\":71,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Mid-teens growth supports premium medtech compounding.\",\"Operating leverage can lift EBIT margin above current ~18%.\",\"High gross margin and cash flow fund innovation and bolt-ons.\",\"Valuation remains rich, limiting upside if growth cools.\",\"Leverage and procedure sensitivity keep risk/reward balanced.\"],\"key_drivers\":[{\"driver\":\"Electrophysiology and structural heart adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Procedure volume growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating leverage from scale\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Product launch cadence\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Bolt-on M&A execution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Hospital budget constraints\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory and recall risk\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Growth decelerates below premium valuation needs.\",\"Regulatory delays or product recalls.\",\"Hospital budget pressure slows procedures.\",\"Integration or overpayment on acquisitions.\",\"Debt and higher rates constrain flexibility.\"],\"assumptions\":{\"revenue_cagr_3y\":11.5,\"ebit_margin_target\":22,\"wacc\":8,\"terminal_multiple\":27},\"scenarios\":{\"bear\":{\"target_price\":56,\"prob\":0.25,\"notes\":\"Multiple compresses as growth normalizes and margins stall.\"},\"base\":{\"target_price\":71,\"prob\":0.5,\"notes\":\"Double-digit growth continues with modest margin expansion.\"},\"bull\":{\"target_price\":83,\"prob\":0.25,\"notes\":\"Strong launches sustain premium growth and valuation.\"}},\"method_notes\":\"Blended 12M valuation using assumed forward EPS growth and EV/EBIT on snapshot fundamentals; base target implies ~13% upside, fitting BUY. Sell-side targets were not used; snapshot quote fields were kept authoritative. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "gpt-5", "risks": [ "Growth decelerates below premium valuation needs.", "Regulatory delays or product recalls.", "Hospital budget pressure slows procedures.", "Integration or overpayment on acquisitions.", "Debt and higher rates constrain flexibility." ], "ticker": "BSX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Double-digit growth continues with modest margin expansion.", "target_price": 71 }, "bear": { "prob": 0.25, "notes": "Multiple compresses as growth normalizes and margins stall.", "target_price": 56 }, "bull": { "prob": 0.25, "notes": "Strong launches sustain premium growth and valuation.", "target_price": 83 } }, "confidence": 0.62, "assumptions": { "wacc": 8, "revenue_cagr_3y": 11.5, "terminal_multiple": 27, "ebit_margin_target": 22 }, "key_drivers": [ { "driver": "Electrophysiology and structural heart adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Procedure volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating leverage from scale", "impact": "HIGH", "direction": "POS" }, { "driver": "Product launch cadence", "impact": "MED", "direction": "POS" }, { "driver": "Bolt-on M&A execution", "impact": "MED", "direction": "POS" }, { "driver": "Premium valuation multiple", "impact": "HIGH", "direction": "NEG" }, { "driver": "Hospital budget constraints", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory and recall risk", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended 12M valuation using assumed forward EPS growth and EV/EBIT on snapshot fundamentals; base target implies ~13% upside, fitting BUY. Sell-side targets were not used; snapshot quote fields were kept authoritative. not investment advice", "current_price": 62.56, "recommendation": "BUY", "thesis_bullets": [ "Mid-teens growth supports premium medtech compounding.", "Operating leverage can lift EBIT margin above current ~18%.", "High gross margin and cash flow fund innovation and bolt-ons.", "Valuation remains rich, limiting upside if growth cools.", "Leverage and procedure sensitivity keep risk/reward balanced." ], "target_price_6m": 67, "target_price_12m": 71 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0048d273e391d88b0069d756bae7f48195bc213e69adf3a91a", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 28356, "createdAt": "2026-04-09T05:19:53.185Z", "usage": { "inputTokens": 2387, "outputTokens": 1517, "costUsd": 0.025415 } }, { "id": "cmnr12mw802imp658b2e4x490", "runId": "cmnr12mw402iip6585zcn7csv", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Hybrid DCF Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"BSX\",\n \"currency\": \"USD\",\n \"current_price\": 62.56,\n \"target_price_6m\": 68,\n \"target_price_12m\": 74,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Strong 20% YOY revenue growth in key medtech segments\",\n \"Robust EPS expansion yet high PEG over 4x signals caution\",\n \"Pullback to 52w low creates entry amid innovation pipeline\",\n \"Margin gains expected but competition may limit upside\",\n \"Solid FCF funds R&D while debt levels warrant monitoring\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Procedure volume recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New product launches\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Valuation de-rating\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"EBIT margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medtech industry competition\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approvals\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macro impact on elective procedures\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Intense competition from peers like MDT and ABT\",\n \"High valuation multiple may contract further\",\n \"Regulatory delays on new device approvals\",\n \"Elevated debt burden in rising rate environment\",\n \"Potential slowdown in hospital capital spending\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.12,\n \"ebit_margin_target\": 0.23,\n \"wacc\": 0.085,\n \"terminal_multiple\": 28\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 53,\n \"prob\": 0.3,\n \"notes\": \"Growth decelerates on competition and macro headwinds.\"\n },\n \"base\": {\n \"target_price\": 74,\n \"prob\": 0.5,\n \"notes\": \"Steady execution on pipeline and margins.\"\n },\n \"bull\": {\n \"target_price\": 90,\n \"prob\": 0.2,\n \"notes\": \"Accelerated adoption beats expectations.\"\n }\n },\n \"method_notes\": \"DCF with 12% rev CAGR, 23% EBIT target, 8.5% WACC and 28x terminal EV/EBITDA. 18% 12M upside supports BUY despite mixed valuation signals. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Hybrid DCF Model", "risks": [ "Intense competition from peers like MDT and ABT", "High valuation multiple may contract further", "Regulatory delays on new device approvals", "Elevated debt burden in rising rate environment", "Potential slowdown in hospital capital spending" ], "ticker": "BSX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on pipeline and margins.", "target_price": 74 }, "bear": { "prob": 0.3, "notes": "Growth decelerates on competition and macro headwinds.", "target_price": 53 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption beats expectations.", "target_price": 90 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.12, "terminal_multiple": 28, "ebit_margin_target": 0.23 }, "key_drivers": [ { "driver": "Procedure volume recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "New product launches", "impact": "HIGH", "direction": "POS" }, { "driver": "Valuation de-rating", "impact": "MED", "direction": "NEG" }, { "driver": "EBIT margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Medtech industry competition", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration success", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals", "impact": "LOW", "direction": "POS" }, { "driver": "Macro impact on elective procedures", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF with 12% rev CAGR, 23% EBIT target, 8.5% WACC and 28x terminal EV/EBITDA. 18% 12M upside supports BUY despite mixed valuation signals. Not investment advice.", "current_price": 62.56, "recommendation": "BUY", "thesis_bullets": [ "Strong 20% YOY revenue growth in key medtech segments", "Robust EPS expansion yet high PEG over 4x signals caution", "Pullback to 52w low creates entry amid innovation pipeline", "Margin gains expected but competition may limit upside", "Solid FCF funds R&D while debt levels warrant monitoring" ], "target_price_6m": 68, "target_price_12m": 74 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "cc919052-d3aa-966e-b1c5-a801a1598f43", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20428, "createdAt": "2026-04-09T05:19:53.185Z", "usage": { "inputTokens": 2714, "outputTokens": 3493, "costUsd": 0.060537 } } ] } }